Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel + gemcitabine versus paclitaxel + vinorelbine for advanced non-small cell lung cancer
ACTRN12609000946213Phase 3Completed
- Sponsor
- HeCOG
- Start
- Jun 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Paclitaxel + Gemcitabine with Paclitaxel + Vinorelbine (2 arms). Primary endpoint: Survival. Started Jun 2004; status: completed.
02
Drugs
paclitaxelgemcitabinevinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12609000946213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000946213.